Baseline sPD-L1 levels were not significantly associated with clinical outcomes in pancreatic cancer patients treated with chemotherapy [231], NSCLC patients receiving chemotherapy or targeted drug therapy [62] or treated with surgery [233], hepatocellular carcinoma patients treated with radiotherapy [232] or transarterial chemoembolization (TACE) [51], and metastatic clear cell renal cell carcinoma patients receiving bevacizumab [222]. This evidence concerns the gene SPDL1 and familial pancreatic carcinoma.